Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Initial Treatment for Open-Angle Glaucoma—Medical, Laser, or Surgical?

Initial Treatment for Open-Angle Glaucoma—Medical, Laser, or Surgical? fields Eye Hospital, London, England, be considered later in the course of REFERENCES in which newly diagnosed glaucoma treatment for our younger patients. patients were randomized to either Medical therapy of glaucoma 1. Schuman JS. Clinical experience with bri- medication, laser therapy, or surgery, has certainly changed in the last 2 monidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996;41 suggests that early surgery may be most decades. Let us give our patients the (suppl):S27-S37. effective in reducing further visual field benefits of the advances in pharma- 2. Watson P, Stjernschantz J. A six-month, random- loss. However, this study was con- ceutical agents and offer medica- ized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hy- ducted without the benefit of some of tion as a first step in controlling their pertension. Ophthalmology. 1996;103:126-137. the newer medications now available disease. It will give the clinician time 3. Zimmerman TJ. Topical ophthalmic beta block- and the patient demographics of that to understand the concerns of the ers: a comparative review. J Ocul Pharmacol. 1993; 9:373-384. study differ from those of the United patient, and the patient in turn will 4. Netland PA, Weiss http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Initial Treatment for Open-Angle Glaucoma—Medical, Laser, or Surgical?

JAMA Ophthalmology , Volume 116 (2) – Feb 1, 1998

Loading next page...
 
/lp/american-medical-association/initial-treatment-for-open-angle-glaucoma-medical-laser-or-surgical-Wt1KyLe561
Publisher
American Medical Association
Copyright
Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/archopht.116.2.240
Publisher site
See Article on Publisher Site

Abstract

fields Eye Hospital, London, England, be considered later in the course of REFERENCES in which newly diagnosed glaucoma treatment for our younger patients. patients were randomized to either Medical therapy of glaucoma 1. Schuman JS. Clinical experience with bri- medication, laser therapy, or surgery, has certainly changed in the last 2 monidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996;41 suggests that early surgery may be most decades. Let us give our patients the (suppl):S27-S37. effective in reducing further visual field benefits of the advances in pharma- 2. Watson P, Stjernschantz J. A six-month, random- loss. However, this study was con- ceutical agents and offer medica- ized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hy- ducted without the benefit of some of tion as a first step in controlling their pertension. Ophthalmology. 1996;103:126-137. the newer medications now available disease. It will give the clinician time 3. Zimmerman TJ. Topical ophthalmic beta block- and the patient demographics of that to understand the concerns of the ers: a comparative review. J Ocul Pharmacol. 1993; 9:373-384. study differ from those of the United patient, and the patient in turn will 4. Netland PA, Weiss

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Feb 1, 1998

References